RBC Capital analyst Luca Issi maintained a Hold rating on RegenXBio today and set a price target of $55.00. The company’s shares closed last Monday at $43.40.
According to TipRanks.com, Issi has 0 stars on 0-5 stars ranking scale with an average return of -8.5% and a 29.3% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Crispr Therapeutics AG.
RegenXBio has an analyst consensus of Moderate Buy, with a price target consensus of $67.40, which is a 67.2% upside from current levels. In a report released yesterday, Leerink Partners also maintained a Hold rating on the stock with a $44.00 price target.
Mirum Pharmaceuticals (MIRM)
In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $51.00. The company’s shares closed last Monday at $17.93.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 12.8% and a 48.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, NGM Biopharmaceuticals, and Intellia Therapeutics.
Currently, the analyst consensus on Mirum Pharmaceuticals is a Strong Buy with an average price target of $48.86, which is a 164.1% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $37.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.